Report of Dolutegravir & Rilpivirine Combination Drug Market is currently supplying a comprehensive analysis of many things which are liable for economy growth and factors which could play an importan
Structure of Q148K HIV-1 intasome with Dolutegravir bound Descriptor: (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa
Background: Nonnucleoside reverse transcriptase inhibitor–based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons. Objective: To evaluate 3 nonnucleoside reverse tran
